Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;26(3):1-4.

Bimekizumab for Moderate-to-Severe Plaque Psoriasis

Ryan D Gotesman  1 , Ron Vender  2
Affiliations
  • PMID: 34077151
Free article

Bimekizumab for Moderate-to-Severe Plaque Psoriasis

Ryan D Gotesman et al. Skin Therapy Lett. 2021 May.
Free article

Abstract

Psoriasis is an immune-mediated inflammatory skin disease that affects about 2% of the population and is associated with many comorbidities. Recent advances have demonstrated interleukin (IL)-17 signaling plays a crucial role in the pathogenesis of psoriasis. Bimekizumab is a novel monoclonal antibody treatment for psoriasis that uses a single binding site to inhibit IL-17A and IL-17F. Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis.

Keywords: IL-17; bimekizumab; interleukin-17A; interleukin-17F; plaque psoriasis.

PubMed Disclaimer

Conflict of interest statement

Ryan Gotesman has no conflicts of interest to disclose. Ron Vender has been a consultant, and/or scientific advisor, and/or investigator, and/or speaker for Amgen, AbbVie, Astellas, Bausch Health/Valeant, BMS, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK, Janssen, Leo Pharma, Merck (MSD), Merck Serono, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda and UCB.

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources